Pulmonx Reports $0.25 EPS Loss, Beats Revenue by 3.97%, Shares Down 30.8%
Pulmonx posted a Q4 adjusted loss of $0.25 per share, beating estimates by 35.9% and narrowing from a $0.33 loss a year earlier. Revenue totaled $22.6 million, topping forecasts by 3.97%, while shares have slid 30.8% since January.
1. Q4 Financial Results
Pulmonx recorded an adjusted net loss of $0.25 per share for the quarter ended December 2025, compared to a loss of $0.33 per share in the same period last year.
2. Earnings and Revenue Surprises
The $0.25 loss represented a 35.9% positive surprise versus consensus, while revenue of $22.6 million beat forecasts by 3.97%. This marks the fourth consecutive quarter outperforming EPS and revenue estimates.
3. Stock Performance
Pulmonx shares have declined 30.8% year-to-date, underperforming the broader market as investors focus on profitability trajectory.
4. Outlook and Industry Context
Consensus forecasts project a Q1 loss of $0.33 per share on $22.25 million in sales, with full-year revenue estimated at $93.86 million and EPS of -$1.28. The medical information systems industry ranks in the lower 40%, highlighting sector headwinds.